Contagion Live: Redefining HIV management: Emerging antiretroviral drug classes and immunologic strategies shaping the future of HIV treatment, prevention
The article discusses the evolution of HIV management, highlighting the shift from daily oral antiretroviral therapy to long-acting and less frequent dosing strategies. It emphasizes the importance of patient-centered outcomes, such as reducing pill fatigue and toxicity, in the future of HIV treatment.
Why it matters
Advancements in HIV treatment significantly improve the quality of life and long-term health outcomes for millions of people living with the virus.
Over the past 3 decades, antiretroviral therapy (ART) has transformed HIV from a universally fatal infection into a manageable chronic disease. Modern integrase strand transfer inhibitor (INSTI)–based regimens achieve virologic suppression in over 90% of treated individuals, resulting in life expectancy comparable to that of the general population. Despite these advances, important limitations remain. With daily oral ART, people with HIV face challenges with adherence and stigma; meanwhile, lifelong therapy contributes to pill fatigue, polypharmacy, and risk of drug resistance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in